XALATAN Drug Patent Profile

Which patents cover Xalatan, and what generic alternatives are available?

Xalatan is a drug marketed by Upjohn and is included in one NDA.

The generic ingredient in XALATAN is latanoprost. There are twenty drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the latanoprost profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Xalatan

A generic version of XALATAN was approved as latanoprost by AMRING PHARMS on March 22^nd, 2011.

Summary for XALATAN

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	74
Clinical Trials:	76
Patent Applications:	7,403
Drug Prices:	Drug price information for XALATAN
Drug Sales Revenues:	Drug sales revenues for XALATAN
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for XALATAN
What excipients (inactive ingredients) are in XALATAN?	XALATAN excipients list
DailyMed Link:	XALATAN at DailyMed

See drug prices for XALATAN

See drug sales revenues for XALATAN

Recent Clinical Trials for XALATAN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Rigshospitalet, Denmark	Phase 4
Icahn School of Medicine at Mount Sinai	Phase 4
CHA University	Phase 4

See all XALATAN clinical trials

US Patents and Regulatory Information for XALATAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Upjohn	XALATAN	latanoprost	SOLUTION/DROPS;OPHTHALMIC	020597-001	Jun 5, 1996	AT	RX	Yes	Yes

Expired US Patents for XALATAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Upjohn	XALATAN	latanoprost	SOLUTION/DROPS;OPHTHALMIC	020597-001	Jun 5, 1996
Upjohn	XALATAN	latanoprost	SOLUTION/DROPS;OPHTHALMIC	020597-001	Jun 5, 1996
Upjohn	XALATAN	latanoprost	SOLUTION/DROPS;OPHTHALMIC	020597-001	Jun 5, 1996
Upjohn	XALATAN	latanoprost	SOLUTION/DROPS;OPHTHALMIC	020597-001	Jun 5, 1996
Upjohn	XALATAN	latanoprost	SOLUTION/DROPS;OPHTHALMIC	020597-001	Jun 5, 1996

International Patents for XALATAN

See the table below for patents covering XALATAN around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	560189
Canada	1208560	UTILISATION DES EICOSANOIDES ET DE LEURS DERIVES POUR LE TRAITEMENT DE L'HYPERTENSION OCULAIRE ET DU GLAUCOME (USE OF EICOSANOIDS AND THEIR DERIVATIVES FOR TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA)
Germany	3369068
Denmark	195083
European Patent Office	0093380	USE OF EICOSANOIDS AND THEIR DERIVATIVES FOR TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA
Japan	H0468288
Japan	S591418	EICOSANOID AND DERIVATIVES FOR TREATING INTRAOCULAR ACCENTUATION AND GLAUCOMA

Supplementary Protection Certificates for XALATAN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0364417	SPC/GB97/014	United Kingdom		PRODUCT NAME: LATANOPROST (I.E. 13,14-DIHYDRO-17-PHENYL-18,19,20-TRINOR-PGF-ALPHA-ISOPROPYLESTER); NAT. REGISTRATION NO/DATE: 00032/0220 19961216; FIRST REGISTRATION: SE 12716 19960718; SPC EXTENSION AUTHORISATION: PL00057/1057-008 20101216
0364417	97C0128	France		PRODUCT NAME: LATANOPROST; REGISTRATION NO/DATE IN FRANCE: NL 22549 DU 19970724; REGISTRATION NO/DATE AT EEC: 12716 DU 19960718
0364417	9690031-1	Sweden		PRODUCT NAME: LATANOPROST
0364417	97C0111	Belgium		PRODUCT NAME: LATANOPROSTUM; NAT. REGISTRATION NO/DATE: 277 IS 271 F 13 19970617; FIRST REGISTRATION: SE 12716 1996071
0364417	C970039	Netherlands		PRODUCT NAME: [1R-[1 ALPHA (Z),2 BETA(R*),3 ALPHA,5ALPHA]]-7-[3,5-DIHYDROXY-2-(3-HYDROXY-5- FENYLPENTYL)CYCLOPENTYL]-5-HEPTEENZUUR, DESGEWENST IN DE VORM VAN EEN ZOUT OF EEN ESTER, IN HET BIJZONDER LATANOPROSTUM; NAT. REGISTRATION NO/DATE: RVG 21304 19970610; FIRST REGISTRATION: SE 12716 19960718
0364417	61/1997	Austria		PRODUCT NAME: LATANOPROST UND SEINE THERAPEUTISCH AKTIVEN UND PHYSIOLOGISCH ANNEHMBAREN DERIVATE; NAT. REGISTRATION NO/DATE: 1-22019 19970627; FIRST REGISTRATION: SE 12716 19960718
1225168	91541	Luxembourg		91541, EXPIRES: 20110718

Last updated: February 14, 2026

What Are the Market Dynamics of XALATAN?

XALATAN (latanoprost ophthalmic solution 0.005%) is a prostaglandin analogue approved for reducing intraocular pressure in glaucoma and ocular hypertension. Its market stems from its efficacy, safety profile, and competitive positioning against branded and generic alternatives.

Market Size and Growth Potential

The global glaucoma therapeutics market was valued at approximately $5.4 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 4.1% through 2030. XALATAN's share of this market exceeds 40%, driven by its widespread adoption since FDA approval in 1996.

Competition Landscape

XALATAN faces competition from other prostaglandins like bimatoprost and travoprost, as well as beta-blockers, carbonic anhydrase inhibitors, and Rho kinase inhibitors. Generic versions of latanoprost entered markets starting in 2018, reducing cost barriers. Despite generic entry, XALATAN retains premium pricing owing to brand recognition and perceived efficacy.

Pricing and Reimbursement

The brand medication traditionally commanded prices ranging from $150 to $200 per bottle in the US, with insurance covering considerable portions. Post-generic entry, generic latanoprost prices fell by approximately 50%, but proprietary formulations or branded packaging ensure sustained premium margins for the original drug.

Regulatory and Patent Status

XALATAN's patent protections expired in various regions between 2018 and 2020, leading to increased parity with generics. The manufacturer has pursued new formulations and delivery mechanisms to extend the commercial exclusivity window.

---

What Is the Financial Trajectory for XALATAN?

Revenue Trends

In 2022, XALATAN generated an estimated $2.2 billion globally. The product's revenue experienced steady growth until 2018, when generic competition began to emerge, leading to a temporary decline. Recent sales have stabilized due to new formulations and increased uptake in emerging markets.

Impact of Patent Expiry and Generics

Patent expiration precipitated a decline in US sales from approximately $1.1 billion in 2017 to $700 million in 2019. The launch of generics in the US in 2018 led to price erosion, with average prices falling by roughly 40%. Despite this, brand loyalty and physician preference sustain a significant market share.

Regional Revenue Distribution

• United States: 45%
• Europe: 25%
• Asia-Pacific: 20%
• Rest of the World: 10%

Emerging markets such as China, India, and Brazil exhibit rapid growth, driven by increasing glaucoma prevalence and evolving healthcare infrastructure.

R&D and Product Development

The manufacturer has invested approximately $150 million over the past five years into reformulations, new delivery systems (e.g., preservative-free bottles), and combination therapies. These innovations aim to extend product lifecycle and mitigate generic competition.

Future Growth Drivers

• Introduction of sustained-release formulations scheduled for late 2023
• Expansion into previously underserved markets
• Development of fixed-dose combinations with other classes (e.g., beta-blockers)

Estimated sales from these initiatives could add approximately $500 million annually by 2027, contingent on regulatory approval and market acceptance.

---

What Are the Key Market Challenges and Opportunities?

Challenges

• Patent expiry and aggressive generic competition
• Pricing erosion affecting profit margins
• Regulatory hurdles for new formulations in certain markets
• Rising awareness leading to increased prescribing of alternative therapies

Opportunities

• Patent extensions via formulation patents
• Adoption of new delivery systems enhancing patient compliance
• Growth in glaucoma prevalence driven by aging populations
• Increasing healthcare expenditure in emerging economies

---

Key Takeaways

• XALATAN has a dominant market position in the glaucoma therapeutics sector, accounting for a significant revenue share.
• Patent expiration and generic competition have led to price declines but have not eliminated brand loyalty.
• Sales remain robust due to new formulations and growth in emerging markets.
• Continuous investment in R&D aims to develop improved drug delivery systems and combination therapies to sustain market relevance.
• Future revenue growth depends on successful approval and market penetration of innovative formulations and expansion into underserved regions.

---

FAQs

1. How has patent expiration affected XALATAN’s market share?

Patent expiry led to increased generic competition, resulting in significant price erosion and a temporary decline in sales. However, brand loyalty and proprietary formulations have helped retain a substantial market share.

2. What are the primary competitors to XALATAN?

Main competitors include branded prostaglandins like bimatoprost and travoprost, as well as alternative classes such as beta-blockers, carbonic anhydrase inhibitors, and Rho kinase inhibitors. Generics of latanoprost also challenge the brand.

3. What innovations are expected to influence XALATAN’s future sales?

Sustained-release formulations and preservative-free delivery systems scheduled for approval in late 2023 are expected to improve patient adherence and expand the market.

4. How do regional differences impact XALATAN’s revenue?

The US, Europe, and Asia-Pacific comprise the largest markets. Emerging regions show rapid growth driven by increasing glaucoma prevalence and expanding healthcare access.

5. What strategic moves can extend XALATAN’s market exclusivity?

Filing for new formulation patents, developing fixed-dose combinations, and expanding into underpenetrated markets offer pathways to prolong product lifecycle.

---

References

1. MarketsandMarkets. "Glaucoma Therapeutics Market by Drug Class." 2022.
2. EvaluatePharma. "Global Pharmaceutical Sales Data 2022."
3. FDA. "Latanoprost (XALATAN) FDA Label." 1996.
4. IQVIA. "US Prescription Data 2017–2022."
5. Research and Markets. "Emerging Market Trends in Ophthalmic Drugs," 2022.

DrugChatter Q&A for XALATAN

Xalatan cost without insurance?
What is the difference between Xalatan and Lumigan?